

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 December 2024 (26.12.2024)



(10) International Publication Number
WO 2024/263889 A2

(51) International Patent Classification:
A61K 31/4162 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2024/034979

(22) International Filing Date:
21 June 2024 (21.06.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/510,056 23 June 2023 (23.06.2023) US
63/588,518 06 October 2023 (06.10.2023) US
63/575,674 06 April 2024 (06.04.2024) US
63/659,580 13 June 2024 (13.06.2024) US

(71) Applicant: **BLOSSOMHILL THERAPEUTICS, INC.**
[US/US]; 3525 John Hopkins Court, Suite 100, San Diego,
California 92121 (US).

(72) Inventors: **CUI, Jingrong Jean**; 3525 John Hopkins Court,
Suite 100, San Diego, California 92121 (US). **JIANG,
Ping**; 3525 John Hopkins Court, Suite 100, San Diego, Cal-
ifornia 92121 (US). **DENG, Wei**; 3525 John Hopkins Court,


Suite 100, San Diego, California 92121 (US). **ZHAI, Day-
ong**; 3525 John Hopkins Court, Suite 100, San Diego, Cal-
ifornia 92121 (US). **LI, Danan**; 3525 John Hopkins Court,
Suite 100, San Diego, California 92121 (US).

(74) Agent: **LEWALLEN, Daniel M.**, BARNES & THORN-
BURG LLP, 11 S. Meridian Street, Indianapolis, Indiana
46204 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: COMBINATION THERAPY INVOLVING MACROCYCLIC INDAZOLE COMPOUNDS



(57) Abstract: The present disclosure relates to methods and compositions for treating cancer with a macrocyclic indazole compound in combination with at least one other cancer therapeutic, such as a Bcl-2 inhibitor, a FLT3 inhibitor, a KRAS inhibitor, an ALK inhibitor, a PARP inhibitor, an EGFR inhibitor, a chemotherapy, and the like.

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*